What’s in Ignyta, Inc. (RXDX) After Touching All-Time High?

January 10, 2018 - By Maria Brooks

Investors sentiment decreased to 2.28 in Q3 2017. Its down 0.68, from 2.96 in 2017Q2. It dived, as 14 investors sold Ignyta, Inc. shares while 18 reduced holdings. 35 funds opened positions while 38 raised stakes. 44.98 million shares or 5.65% more from 42.58 million shares in 2017Q2 were reported.
12,451 are owned by Legal & General Gru Public Ltd Company. The Minnesota-based Ameriprise has invested 0% in Ignyta, Inc. (NASDAQ:RXDX). Group Inc One Trading Ltd Partnership holds 0% or 500 shares in its portfolio. California Employees Retirement Systems holds 0% or 61,800 shares in its portfolio. State Street Corporation stated it has 0% of its portfolio in Ignyta, Inc. (NASDAQ:RXDX). Moreover, Fmr Limited Company has 0% invested in Ignyta, Inc. (NASDAQ:RXDX) for 459,631 shares. Pier Ltd Company owns 1.15% invested in Ignyta, Inc. (NASDAQ:RXDX) for 537,618 shares. Axa owns 446,298 shares. Sphera Funds Mngmt Ltd has invested 0.81% in Ignyta, Inc. (NASDAQ:RXDX). Bnp Paribas Arbitrage reported 4,874 shares stake. 39,517 are held by Credit Suisse Ag. 875,515 were reported by Arrowmark Colorado Ltd Limited Liability Company. Highland Mgmt L P accumulated 98,500 shares. Alliancebernstein L P invested 0% in Ignyta, Inc. (NASDAQ:RXDX). Opus Point Partners Management Ltd accumulated 1.89% or 170,500 shares.

The stock of Ignyta, Inc. (NASDAQ:RXDX) reached all time high today, Jan, 10 and still has $28.89 target or 7.00 % above today’s $27.00 share price. This indicates more upside for the $1.83B company. This technical setup was reported by Barchart.com. If the $28.89 PT is reached, the company will be worth $127.75M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events.

It closed at $27 lastly. It is up 14.24% since January 10, 2017 and is uptrending. It has underperformed by 2.46% the S&P500.

Analysts await Ignyta, Inc. (NASDAQ:RXDX) to report earnings on March, 13. They expect $-0.44 EPS, up 34.33 % or $0.23 from last year’s $-0.67 per share. After $-0.51 actual EPS reported by Ignyta, Inc. for the previous quarter, Wall Street now forecasts -13.73 % EPS growth.

Ignyta, Inc. (NASDAQ:RXDX) Ratings Coverage

Among 10 analysts covering Ignyta (NASDAQ:RXDX), 7 have Buy rating, 0 Sell and 3 Hold. Therefore 70% are positive. Ignyta had 20 analyst reports since August 12, 2015 according to SRatingsIntel. The stock of Ignyta, Inc. (NASDAQ:RXDX) earned “Buy” rating by SunTrust on Tuesday, November 21. SunTrust downgraded the shares of RXDX in report on Tuesday, December 26 to “Hold” rating. The rating was initiated by Cantor Fitzgerald on Monday, October 26 with “Buy”. On Monday, July 10 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The rating was downgraded by Ladenburg Thalmann on Tuesday, December 26 to “Neutral”. The firm has “Outperform” rating given on Thursday, January 21 by Credit Suisse. The firm earned “Overweight” rating on Thursday, June 23 by JP Morgan. On Thursday, October 12 the stock rating was maintained by JP Morgan with “Overweight”. The rating was initiated by Cantor Fitzgerald with “Buy” on Tuesday, November 10. The firm has “Overweight” rating given on Wednesday, August 12 by Piper Jaffray.

Another recent and important Ignyta, Inc. (NASDAQ:RXDX) news was published by Fool.com which published an article titled: “Why Ignyta, Inc. Stock Is Soaring Today” on December 22, 2017.

Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. The company has market cap of $1.83 billion. The Company’s products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the tropomyosin receptor kinase family tyrosine kinase receptors, ROS1, and anaplastic lymphoma kinase proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, an orally bioavailable and vascular endothelial growth factor receptor, and small molecule tyrosine kinase inhibitor of RET-driven solid tumors; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.